Amoxicillin
NDC Package 52959-020-42

11-digit billing NDC: 52959002042 · Billing unit: EA · 42 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Amoxicillin is 1.1 Infections of the Ear, Nose, and ThroatAmoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. Marketed by H.j. Harkins Company, Inc., this product is identified by NDC 52959-020 and is authorized under FDA application ANDA065271.

Identification & Billing

NDC Package Code
52959-020-42
Package Description
42 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
52959002042
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
42 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Amoxicillin
Dosage Form
-
Usage Information
1.1 Infections of the Ear, Nose, and ThroatAmoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only),Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae.1.2 Infections of the Genitourinary TractAmoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis.1.3 Infections of the Skin and Skin StructureAmoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcusspp., or E. coli.1.4 Infections of the Lower Respiratory TractAmoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae.1.5 Helicobacter pylori InfectionTriple therapy for Helicobacter pylori with clarithromycin and lansoprazole: Amoxicillin capsules in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole: Amoxicillin capsules, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.6 UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules and other antibacterial drugs, amoxicillin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
H.j. Harkins Company, Inc.
FDA Application #
ANDA065271
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-11-2005
Listing Expiration
12-31-2019
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (52959-020). Click a package code to view its specific billing and regulatory data.

100 CAPSULE in 1 BOTTLE
2 CAPSULE in 1 BOTTLE
3 CAPSULE in 1 BOTTLE
4 CAPSULE in 1 BOTTLE
5 CAPSULE in 1 BOTTLE
6 CAPSULE in 1 BOTTLE
8 CAPSULE in 1 BOTTLE
12 CAPSULE in 1 BOTTLE
15 CAPSULE in 1 BOTTLE
17 CAPSULE in 1 BOTTLE
18 CAPSULE in 1 BOTTLE
20 CAPSULE in 1 BOTTLE
21 CAPSULE in 1 BOTTLE
22 CAPSULE in 1 BOTTLE
24 CAPSULE in 1 BOTTLE
28 CAPSULE in 1 BOTTLE
30 CAPSULE in 1 BOTTLE
32 CAPSULE in 1 BOTTLE
40 CAPSULE in 1 BOTTLE
50 CAPSULE in 1 BOTTLE
60 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 52959-020-42 identifies a specific commercial package of 42 capsule in 1 bottle of Amoxicillin, labeled by H.j. Harkins Company, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 42 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by H.j. Harkins Company, Inc. on September 11, 2005. The current certification is valid through December 31, 2019.

How is this H.j. Harkins Company, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 52959002042. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 42 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
52959-020-42
11-Digit CMS (5-4-2)
52959-0020-42

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.